ABSI vs RXRX
ABSI and RXRX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | ABSIABSCI CORP | RXRXRecursion Pharmaceuticals, Inc. |
|---|---|---|
| Market cap | $1.87B | $2.19B |
| P/S | 666.2x | 29.2x |
| Revenue growth (YoY) | -38.2% | 26.9% |
| Earnings growth (YoY) | -11.7% | -39.1% |
| EBIT margin | -4297.0% | -867.9% |
| ROE | -46.8% | -70.5% |
| ROIC | -84.6% | -175.2% |
| 1y total return | +153.4% | -25.9% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: ABSI vs RXRX
| Metric | ABSI | RXRX |
|---|---|---|
| End value | $5.0K | $1.1K |
| Total return | -49.8% | -88.7% |
| CAGR | -12.2% | -33.8% |
| Volatility | 98.2% | 93.1% |
| Sharpe | 0.31 | -0.05 |
| Sortino | 0.47 | -0.08 |
| Max drawdown | -96.2% | -92.1% |
Based on 1327 common trading days, 2021-07-22 → 2026-11-02 · risk-free 4.16% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)